PL3723807T3 - Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn - Google Patents
Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydynInfo
- Publication number
- PL3723807T3 PL3723807T3 PL18830163T PL18830163T PL3723807T3 PL 3723807 T3 PL3723807 T3 PL 3723807T3 PL 18830163 T PL18830163 T PL 18830163T PL 18830163 T PL18830163 T PL 18830163T PL 3723807 T3 PL3723807 T3 PL 3723807T3
- Authority
- PL
- Poland
- Prior art keywords
- pirazolo
- pyridine
- administration
- combination treatment
- treatment including
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 238000011284 combination treatment Methods 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700708 | 2017-12-14 | ||
| PCT/EP2018/084432 WO2019115566A1 (en) | 2017-12-14 | 2018-12-12 | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
| EP18830163.4A EP3723807B1 (en) | 2017-12-14 | 2018-12-12 | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3723807T3 true PL3723807T3 (pl) | 2022-01-24 |
Family
ID=64959282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18830163T PL3723807T3 (pl) | 2017-12-14 | 2018-12-12 | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11634416B2 (pl) |
| EP (1) | EP3723807B1 (pl) |
| JP (1) | JP7261801B2 (pl) |
| KR (1) | KR20200099154A (pl) |
| CN (1) | CN111465410B (pl) |
| AR (1) | AR113931A1 (pl) |
| AU (1) | AU2018385453B2 (pl) |
| BR (1) | BR112019016815A2 (pl) |
| CA (1) | CA3085201A1 (pl) |
| CL (1) | CL2020001548A1 (pl) |
| CO (1) | CO2020007129A2 (pl) |
| CY (1) | CY1124751T1 (pl) |
| ES (1) | ES2899868T3 (pl) |
| HR (1) | HRP20211784T1 (pl) |
| HU (1) | HUE057202T2 (pl) |
| IL (1) | IL275290B2 (pl) |
| LT (1) | LT3723807T (pl) |
| MX (1) | MX2020006174A (pl) |
| PL (1) | PL3723807T3 (pl) |
| PT (1) | PT3723807T (pl) |
| RS (1) | RS62551B1 (pl) |
| RU (1) | RU2020118913A (pl) |
| SG (1) | SG11202005361RA (pl) |
| SI (1) | SI3723807T1 (pl) |
| SM (1) | SMT202100655T1 (pl) |
| WO (1) | WO2019115566A1 (pl) |
| ZA (1) | ZA202003514B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| PL3723807T3 (pl) | 2017-12-14 | 2022-01-24 | H. Lundbeck A/S | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| WO2019121840A1 (en) * | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| JP5092402B2 (ja) | 2004-07-05 | 2012-12-05 | アステラス製薬株式会社 | ピラゾロピリジン誘導体 |
| EP1802621B1 (en) * | 2004-10-19 | 2009-05-06 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
| WO2006084251A2 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| RU2402549C3 (ru) | 2005-04-14 | 2022-03-10 | Оцука Фармасьютикал Ко., Лтд. | Пиперазин-замещенные бензотиофены для лечения психических расстройств |
| NZ567540A (en) | 2005-12-22 | 2010-07-30 | Newron Pharm Spa | 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| HRP20120361T1 (hr) * | 2007-03-14 | 2012-05-31 | Ranbaxy Laboratories Limited | DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE |
| WO2010065153A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US8748386B2 (en) | 2009-06-10 | 2014-06-10 | New York University | Immunological targeting of pathological Tau proteins |
| EP3042917B1 (en) | 2010-08-12 | 2018-02-21 | Eli Lilly and Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| MX365784B (es) | 2011-04-21 | 2019-05-28 | Origenis Gmbh | Compuestos heterociclicos como inhibidores de cinasas. |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| UA116023C2 (uk) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| GEAP201814248A (en) | 2014-02-19 | 2018-04-10 | H Lundbeck As | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| CA2961186A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| TW201643167A (zh) | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| BR112017007472A2 (pt) | 2015-08-12 | 2018-01-23 | H Lundbeck As | 2-amino-3-fluoro-3-(fluoro metil)-6-metil-6-fenil- 3,4,5,6-tetra-hidropiridinas como inibidores de bace1 |
| US20180344680A1 (en) | 2015-12-08 | 2018-12-06 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers |
| US10390177B2 (en) | 2015-12-09 | 2019-08-20 | Ford Global Technologies, Llc | Alert for left-behind mobile device |
| WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| PL3723807T3 (pl) | 2017-12-14 | 2022-01-24 | H. Lundbeck A/S | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| WO2019121840A1 (en) * | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| TW201927784A (zh) * | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
-
2018
- 2018-12-12 PL PL18830163T patent/PL3723807T3/pl unknown
- 2018-12-12 ES ES18830163T patent/ES2899868T3/es active Active
- 2018-12-12 RU RU2020118913A patent/RU2020118913A/ru unknown
- 2018-12-12 AU AU2018385453A patent/AU2018385453B2/en not_active Expired - Fee Related
- 2018-12-12 HR HRP20211784TT patent/HRP20211784T1/hr unknown
- 2018-12-12 LT LTEPPCT/EP2018/084432T patent/LT3723807T/lt unknown
- 2018-12-12 MX MX2020006174A patent/MX2020006174A/es unknown
- 2018-12-12 KR KR1020207019016A patent/KR20200099154A/ko not_active Ceased
- 2018-12-12 PT PT188301634T patent/PT3723807T/pt unknown
- 2018-12-12 JP JP2020531953A patent/JP7261801B2/ja active Active
- 2018-12-12 CA CA3085201A patent/CA3085201A1/en active Pending
- 2018-12-12 WO PCT/EP2018/084432 patent/WO2019115566A1/en not_active Ceased
- 2018-12-12 RS RS20211372A patent/RS62551B1/sr unknown
- 2018-12-12 CN CN201880079962.7A patent/CN111465410B/zh active Active
- 2018-12-12 SM SM20210655T patent/SMT202100655T1/it unknown
- 2018-12-12 HU HUE18830163A patent/HUE057202T2/hu unknown
- 2018-12-12 BR BR112019016815-0A patent/BR112019016815A2/pt not_active IP Right Cessation
- 2018-12-12 US US16/772,561 patent/US11634416B2/en active Active
- 2018-12-12 SG SG11202005361RA patent/SG11202005361RA/en unknown
- 2018-12-12 EP EP18830163.4A patent/EP3723807B1/en active Active
- 2018-12-12 SI SI201830453T patent/SI3723807T1/sl unknown
- 2018-12-13 AR ARP180103639A patent/AR113931A1/es unknown
-
2020
- 2020-06-10 CL CL2020001548A patent/CL2020001548A1/es unknown
- 2020-06-11 CO CONC2020/0007129A patent/CO2020007129A2/es unknown
- 2020-06-11 ZA ZA2020/03514A patent/ZA202003514B/en unknown
- 2020-06-11 IL IL275290A patent/IL275290B2/en unknown
-
2021
- 2021-11-25 CY CY20211101025T patent/CY1124751T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3723807T (pt) | 2021-11-26 |
| ZA202003514B (en) | 2022-12-21 |
| CN111465410B (zh) | 2022-10-25 |
| CA3085201A1 (en) | 2019-06-20 |
| RS62551B1 (sr) | 2021-12-31 |
| HUE057202T2 (hu) | 2022-04-28 |
| RU2020118913A (ru) | 2022-01-14 |
| JP2021506775A (ja) | 2021-02-22 |
| JP7261801B2 (ja) | 2023-04-20 |
| AU2018385453A1 (en) | 2020-07-02 |
| SMT202100655T1 (it) | 2022-01-10 |
| KR20200099154A (ko) | 2020-08-21 |
| CL2020001548A1 (es) | 2020-09-25 |
| SG11202005361RA (en) | 2020-07-29 |
| ES2899868T3 (es) | 2022-03-15 |
| AU2018385453B2 (en) | 2024-02-08 |
| BR112019016815A2 (pt) | 2020-04-07 |
| EP3723807B1 (en) | 2021-10-20 |
| MX2020006174A (es) | 2022-09-27 |
| US11634416B2 (en) | 2023-04-25 |
| IL275290B2 (en) | 2023-06-01 |
| HRP20211784T1 (hr) | 2022-02-18 |
| WO2019115566A1 (en) | 2019-06-20 |
| US20200385381A1 (en) | 2020-12-10 |
| LT3723807T (lt) | 2021-12-10 |
| CO2020007129A2 (es) | 2020-06-19 |
| CN111465410A (zh) | 2020-07-28 |
| SI3723807T1 (sl) | 2022-01-31 |
| AR113931A1 (es) | 2020-07-01 |
| IL275290A (en) | 2020-07-30 |
| CY1124751T1 (el) | 2022-07-22 |
| EP3723807A1 (en) | 2020-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3846904T3 (da) | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| HUE051067T2 (hu) | N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik | |
| IL268850A (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| DK3889145T3 (da) | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme | |
| PL3896064T3 (pl) | Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego | |
| DK3355884T3 (da) | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler | |
| HUE051448T2 (hu) | Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére | |
| EP3452481A4 (en) | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| LT3371179T (lt) | Nauji kriptoficino junginiai ir konjugatai, jų gavimas ir terapinis panaudojimas | |
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| IL268905B (en) | Phage therapy | |
| SI3452465T1 (sl) | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni | |
| PL3723807T3 (pl) | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn | |
| IL275293B1 (en) | Combined treatments that include the administration of h1 - pyrazolo[4, 3-b]pyridines | |
| MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
| PL3597648T3 (pl) | METODA WYTWARZANIA 3,6-DIPODSTAWIONEJ POCHODNEJ IMIDAZO[1, 2-b]PIRYDAZYNY | |
| IL274868A (en) | History of imidazopyridine and their use as medicine | |
| EP3395381C0 (en) | RADIOPAQUE STRUCTURE AND IMPLANTABLE MEDICAL DEVICE COMPRISING THE RADIOPAQUE STRUCTURE | |
| LT3649109T (lt) | Etinilo junginiai, jų gamyba ir jų terapinis panaudojimas maliarijos gydymui | |
| EP3621618A4 (en) | TREATMENT OF GASTROPARESIA USING TRIAZASPIRO (4.5) DECANONE | |
| EP3426264A4 (en) | IMMUNOGENIC COMBINATION THERAPY | |
| TH1501006890A (th) | อนุพันธ์ไพริโดนสำหรับการบำบัดการติดเชื้อไวรัสและโรคอื่นเพิ่มเติม |